Biotricity, Inc. - Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)		3 Months Ended
		Mar. 31, 2016		Mar. 31, 2015
Income Statement
Revenue
Expenses:
General and administrative expenses	[1]	$ 335,086		$ 1,439,211
Research and development expenses	[2]	241,534		367,194
Total Operating Expenses		576,620		$ 1,806,405
Accretion expense	[3]	73,572
Change in fair value of derivative liabilities		618,959	[4]
Net loss before income taxes		$ (1,269,151)		$ (1,806,405)
Income taxes
Net loss		$ (1,269,151)		$ (1,806,405)
Translation adjustment		(61,518)		(133,930)
Net loss and comprehensive loss		$ (1,330,669)		$ (1,940,335)
Loss per share, basic and diluted		$ (0.0508)		$ (0.0723)
Weighted average common and exchangeable shares outstanding		24,999,978		24,999,978

[1] See Notes 10 and 11

[2] See Note 11

[3] See Note 7

[4] See Note 8